Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance by Ng, Yen-Shing et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 
©
 
 The Rockefeller University Press • 0022-1007/2004/10/927/8 $8.00
Volume 200, Number 7, October 4, 2004 927–934
http://www.jem.org/cgi/doi/10.1084/jem.20040920
 
927
 
Bruton’s Tyrosine Kinase Is Essential for 
Human B Cell Tolerance
 
Yen-Shing Ng,
 
1 
 
Hedda Wardemann,
 
3 
 
James Chelnis,
 
1 
 
Charlotte Cunningham-Rundles,
 
4 
 
and Eric Meffre
 
1,2
 
1
 
Laboratory of Biochemistry and Molecular Immunology, The Hospital for Special Surgery, and 
 
2
 
Weill Medical 
College of Cornell University, New York, NY 10021
 
3
 
Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10021
 
4
 
Department of Medicine and Pediatrics, Mount Sinai Medical Center, New York, NY 10029
 
Abstract
 
Most polyreactive and antinuclear antibodies are removed from the human antibody repertoire
during B cell development. To elucidate how B cell receptor (BCR) signaling may regulate
human B cell tolerance, we tested the specificity of recombinant antibodies from single periph-
eral B cells isolated from patients suffering from X-linked agammaglobulinemia (XLA). These
patients carry mutations in the Bruton’s tyrosine kinase (
 
BTK
 
) gene that encode an essential
BCR signaling component. We find that in the absence of Btk, peripheral B cells show a distinct
antibody repertoire consistent with extensive secondary V(D)J recombination. Nevertheless,
XLA B cells are enriched in autoreactive clones. Our results demonstrate that Btk is essential in
regulating thresholds for human B cell tolerance.
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Introduction
 
In humans, Ig gene recombination produces large numbers
of self-reactive antibodies or B cell receptors (BCRs; refer-
ence 1). Most of the polyreactive antibodies and antinu-
clear antibodies (ANAs) are removed from the repertoire
during B cell development, thereby ensuring self-tolerance
(1). In mice, three mechanisms account for the silencing of
newly arising autoreactive B cells: deletion, anergy, and
receptor editing (2–5). These tolerance mechanisms are
triggered and regulated by antigen binding to self-reactive
BCRs. For example, transgenic and knockout mouse ex-
periments have shown that BCR signaling thresholds are
essential in B cell tolerance (6). Changes in tuning func-
tions of the BCR coreceptors such as CD19 or CD22 and
PD-1 and their associated signaling molecules Lyn and
SHIP all impact on the tolerance response (7–10). Much
less is known about the mechanisms that regulate B cell
tolerance in humans.
Defects in BCR signaling have been reported in B cells
from immunodeficient patients with common variable im-
munodeficiency who frequently develop autoimmunity,
suggesting that BCR signaling may play an important role
in counterselecting self-reactive B cells (11). To investi-
gate the role of BCR signaling in the regulation of autore-
active B cells in humans, we analyzed tolerance in B cells
from X-linked agammaglobulinemia (XLA) patients. XLA
or Bruton’s disease is characterized by a severe decrease of
peripheral B cells and serum Ig (12, 13). Genetic studies in
humans led to the identification of the defective gene,
named Bruton’s tyrosine kinase (
 
BTK
 
) gene, which en-
codes a cytoplasmic tyrosine kinase that plays an essential
role in mediating BCR signaling (14, 15). Although B cell
differentiation is severely affected at the pro- to pre-B
transition, a few B cells develop and migrate to the periph-
ery where they fail to accumulate (12, 16, 17). XLA has
a more severe phenotype in humans than murine Xid,
which results from loss of function of the murine 
 
btk
 
 gene
(18). In 
 
btk
 
 
 
/
 
  
 
mice, peripheral B cells are observed but
responses to T-independent antigen (type II) are impaired,
whereas responses to T-dependent antigens remain normal
(19). Therefore, mouse models for Btk deficiency cannot
be extrapolated to humans. We report that in humans,
central B cell tolerance checkpoints are abrogated in the
absence of Btk.
 
The online version of this article contains supplemental material.
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Materials and Methods
 
Patients.
 
Patients 1 and 2 are adult first cousins who suffer
from a mutation in exon 11 of the 
 
BTK
 
 gene consisting of an 18-
bp insertion (XLA-Ins) resulting from the duplication of neigh-
boring DNA. Patients 3 and 4 are adolescent and preadolescent
brothers who show an adenosine to cytidine substitution in co-
don 117 that results in a proline instead of the wild-type threo-
nine in the pleckstrin homology domain of Btk (XLA-T117P).
All patients showed similarly decreased levels of peripheral B cells
that were mostly CD19
 
  
 
CD10
 
  
 
IgM
 
  
 
CD27
 
  
 
new emigrant B
cells. Control healthy donors were a 23-yr-old female (JH) and a
31-yr-old male (PE). All samples were collected after signed in-
formed consent in accordance with IRB-reviewed protocols.
 
Single Cell Sorting.
 
Peripheral B cells were purified from the
blood of XLA patients and from the blood of two nonrelated
healthy donors by negative selection using the RosetteSep pro-
cedure (StemCell Technologies, Inc.). Enriched B cells were
stained with FITC anti–human CD27, PE anti–human CD10,
anti–human IgM-biotin, and allophycocyanin anti-CD19 (BD
Biosciences and Becton Dickinson). Biotinylated antibodies were
revealed using Streptavidin-Red613 (GIBCO BRL). Single
CD19
 
  
 
CD10
 
  
 
IgM
 
  
 
CD27
 
  
 
new emigrant B cells from XLA
patients and control donors were sorted on a FACSVantage (Bec-
ton Dickinson) into 96-well PCR plates containing 4 
 
 
 
l of lysis
solution (0.5
 
  
 
PBS containing 10 mM DTT, 8 U RNAsin
[Promega], and 0.4 U 5
 
 
 
-3
 
  
 
RNase Inhibitor [Eppendorf]) and
immediately frozen on dry ice. All samples were stored at
 
 
 
70
 
 
 
C.
 
cDNA, RT-PCR, Antibody Production, and Purification.
 
RNA
from single cells was reverse transcribed in the original 96-well
plate in 12.5 
 
 
 
l of reactions containing 100 U Superscript II RT
(GIBCO BRL) for 45 min at 37
 
 
 
C. RT-PCR reactions, primer
sequences, cloning strategy, expression vectors, antibody expres-
sion, and purification were as described previously (1). Ig se-
quences were analyzed by Ig BLAST comparison with GenBank.
 
ELISAs and Immunofluorescence Assays.
 
Antibody concentra-
tion, reactivity against specific antigens, and indirect immunoflu-
orescence were as described previously (1). High (polyreactive
ED38) and weak (mGO186) ANA-reactive and -nonreactive
mGO53 and iGO13 were used as positive and negative controls
in self-reactivity and polyreactivity ELISAs (1, 20).
 
Statistical Analysis.
 
Two-tailed p-values were calculated by the
Fisher Exact Test. Bonferroni corrections were used when analyz-
ing unpredictable D gene usage frequency by multiplying the
p-value by the number of parameters. Although some data from
individual patients could reach statistical significance, the frequency
of self-reactive clones was calculated after pooling data from pa-
tients carrying the same 
 
BTK
 
 gene mutation. Because of the very
large number of Ig gene segments, antibody repertoire analyses
were performed after pooling Ig sequences from all XLA patients.
 
Online Supplemental Material.
 
Antibody characteristics from
control new emigrant, XLA-Ins, and XLA-T117P B cells are
presented in Tables S1–S3. Fig. S1 shows antibody features that
differ between nonreactive and polyreactive antibodies from
XLA B cells. Tables S1–S3 and Fig. S1 are available at http://
www.jem.org/cgi/content/full/jem.20040920/DC1.
 
Results
 
Peripheral B Cell Selection in XLA Patients. BTK 
 
gene
encodes a cytoplasmic tyrosine kinase that plays an essential
role in BCR signaling in humans (14, 15, 21, 22). XLA pa-
tients are characterized by a severe decrease in peripheral B
cells and serum Ig levels (12, 13). In line with this observa-
tion, we found that most peripheral blood B cells from
XLA patients were CD19
 
  
 
CD10
 
  
 
IgM
 
  
 
CD27
 
  
 
new emi-
grant B cells that fail to develop into CD19
 
  
 
CD10
 
  
 
IgM
 
 
 
CD27
 
  
 
mature naive B cells (Fig. 1; reference 23).
To examine the self-reactivity of the antibodies develop-
ing in the absence of Btk, we cloned antibodies from iso-
lated CD19
 
  
 
CD10
 
  
 
IgM
 
  
 
CD27
 
  
 
new emigrant B cells
from four XLA patients and two healthy donors (refer to
Materials and Methods). Repertoire analysis revealed that
two specific V
 
H 
 
genes, V
 
H
 
1-3 and the self-reactive V
 
H
 
4-34
used in all cold agglutinin antibodies (24, 25), were in-
creased in Btk-deficient B cells and encoded up to 25% (21
out of 91) of all antibodies in XLA patients (Fig. 2, A and
B). In contrast, V
 
H
 
1-3 and V
 
H
 
4-34 genes represented only
7.3% (8 out of 109) of the antibodies from control new
emigrant B cells (P 
 
  
 
0.002; Tables S1–S3, available at
http://www.jem.org/cgi/content/full/jem.20040920/
DC1). In addition, the antibody repertoire of XLA B cells
was devoid of V
 
H
 
4-59, a gene commonly used in B cells
from healthy donors (P 
 
  
 
0.008; Fig. 2 B; references 1 and
26). Human antibodies show preferential use of certain D
segments that are mostly used in the hydrophilic reading
frame (RF; reference 27). We found that D6 gene usage
was increased from 15.8% in control new emigrant to 35%
in XLA B cells (P 
 
  
 
0.028 after Bonferroni correction; Fig.
2 C). When combined, D2, D5, and D6 family members
in hydrophobic RFs were increased from 35.5% in control
new emigrant to 58.3% in XLA B cells (P 
 
  
 
0.038),
whereas those that used the hydrophilic RFs decreased
from 57.8% in control to 31.25% in XLA B cells (P 
 
 
 
0.013; Fig. 2 D). We conclude that XLA B cells are se-
lected to express a unique antibody repertoire using distinct
Figure 1. Peripheral XLA B cell are new emigrant B cells. Dot plots
show CD10, IgM (top), CD10, and CD27 (bottom) expression on gated
CD19  B cells in a control (left) and XLA patient (right). Most peripheral
blood B cells from XLA patients were CD19  CD10  IgM  CD27  new
emigrant B cells that fail to develop into CD19  CD10  IgM  CD27 
mature naive B cells. 
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V
 
H 
 
and D genes that favor hydrophobic RFs that are nor-
mally counterselected in B cells from healthy donors.
 
Increased Secondary V(D)J Recombination in XLA B Cells.
 
In addition to their unique heavy chain repertoire, XLA B
cells also display remarkable light chains. We found that
Ig
 
  
 
genes from XLA patients had decreased J
 
 
 
1 usage
(11.5% in XLA vs. 28.5% in control new emigrant B cells;
P 
 
  
 
0.038) and increased J
 
 
 
5 usage (28% in XLA vs. 8.5%
in control new emigrant B cells; P 
 
  
 
0.0086), suggesting
extensive secondary V(D)J recombination on the Ig
 
  
 
locus
(Fig. 3 A). In contrast, control new emigrant B cells prefer-
entially use J
 
 
 
1 and J
 
 
 
2 segments (
 
n 
 
  
 
70 from four
healthy donors; Fig. 3 A and Table S1). XLA B cells also
showed a V
 
  
 
gene usage biased to upstream V
 
 
 
s consistent
with secondary recombination events (P 
 
  
 
0.0045; Fig. 3
B). An apparent exception to this rule was the increased
V
 
 
 
4-1 usage, the most downstream of all V
 
 
 
s (16.25% in
XLA patient vs. 1.5% in control new emigrant B cells; P 
 
 
 
0.0047; Fig. 3 B; references 20 and 28). However, V
 
 
 
4-1
rearrangements may correspond to secondary recombina-
tion events because of their inverse orientation on the Ig
 
 
 
locus (29). IgL gene rearrangements follow an ordered pro-
cess where Ig
 
  
 
genes rearrange before Ig
 
  
 
genes (30). In
addition to the apparent increase in Ig
 
  
 
gene secondary re-
Figure 2. XLA B cells are a highly selected B cell
population with a unique VH and D gene usage. Pro-
portions of VH1 (A), VH4 (B), D family (C) gene, and
RF (D) usage in control new emigrant (open bars) and
XLA B cells (closed bars). Control new emigrant B cell
sequences included sequences shown in Table S1 and
as reported previously (reference 1). D RF usage for
combined D2, D5, and D6 family gene segments rep-
resented in panel D was assigned according to Corbett
et al. (reference 27). *, statistically significant difference.
P-values for differences between fractions are stated in
the text and were calculated by the Fisher Exact Test.
Figure 3. Extensive Ig  secondary recombination in
XLA B cells. J  (A) and V  (B) usage in control new
emigrant and XLA B cells. Control new emigrant B
cell sequences included sequences shown in Table S1
and as reported previously (reference 1). Pie charts
show proportion of different J  genes. The number of
sequences analyzed in each fraction is indicated below
the pie charts. The proximal V  locus (B) involved in
95% of V –J  rearrangements is shown clustered into
groups of V genes. The percent of each V  group is in-
dicated on the y axis. *, statistically significant differ-
ence. P-values for differences between fractions are
stated in the text and were calculated by the Fisher Ex-
act Test. 
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combination in XLA B cells, we also found an increase in
Ig
 
 
 
-expressing B cells (43 Ig
 
 
 
/51 Ig
 
  
 
in XLA vs. 70 Ig
 
 
 
/
42 Ig
 
  
 
in control new emigrant B cells; P 
 
  
 
0.017). Fur-
ther, Ig
 
  
 
genes from XLA patients showed evidence of in-
creased secondary V(D)J recombination in that there was a
significant decrease of upstream J
 
 
 
1 usage in XLA B cells
(5.9% in XLA vs. 21.4% in control new emigrant B cells;
P   0.032) and a proportional increase in more down-
stream J  usage (Fig. 4 A). When compared with control
new emigrant B cells, XLA B cells showed a significant de-
crease in downstreamV 3 family gene usage (P   0.005)
and an increase in upstream V  gene usage including un-
usual V 4, V 7, V 8, V 9, and V 10 genes (P   0.026;
Fig. 4 B). Our results are consistent with the possibility that
XLA B cells suffered extensive secondary recombination
on both Ig  and Ig  loci.
XLA B Cells Express Self-reactive Antibodies. To deter-
mine whether antibodies expressed by XLA B cells were
self-reactive, we initially tested 65 antibodies cloned from
single XLA new emigrant B cells and 29 antibodies from
control new emigrant B cells for binding to nuclear and cy-
toplasmic antigens (HEp-2 cell line extract), using a stan-
dard clinical ELISA for ANAs (1). Additional control anti-
bodies included a strong (ED38) and a weak (mGO186)
positive control as well as nonself-reactive mGO53 and
iGO13 antibodies (1, 20). In agreement with our previous
report, we found that the proportion of HEp-2 lysate-reac-
tive antibodies expressed by new emigrant B cells (31%)
was similar to that of previous controls (40.7%; P   0.48;
Fig. 5 A; reference 1). In contrast, we found an increase in
the frequency of B cells that expressed HEp-2 lysate-reac-
tive antibodies in both XLA-Ins and XLA-T117P patients
(62.1 and 55.6%, respectively; P   0.025; Fig. 5 A). When
control antibodies were pooled with the previously re-
ported control antibodies isolated from new emigrant B
cells (1), the proportion of HEp-2 lysate-reactive clones in
this compartment reached 37.3% (31 out of 81) and the
p-value for the difference of HEp-2 ELISA-reactive anti-
bodies between control and XLA B cells slightly increased
up to 0.013.
To determine whether XLA self-reactive antibodies were
true ANAs or anti-cytosolic antibodies, we performed in-
direct immunofluorescence assays on fixed HEp-2 cells
(Fig. 5 B). Autoreactive antibodies expressed by XLA B
cells showed either nuclear (X2-20) or nuclear and cyto-
plasmic (X1-30, X2-53, X3-40, X3-69, and X-4-13) stain-
ing patterns (Fig. 5 B). Our observations suggest that
peripheral XLA B cells contained a slightly increased pro-
portion of lymphocytes expressing ANAs.
XLA B Cell Antibodies Are Polyreactive. Because the
HEp-2 ELISA is a crude assay for self-reactivity, we tested
the reactivity of 67 antibodies isolated from XLA B cells
and 31 antibodies from control new emigrant B cells to sin-
gle-stranded DNA, double-stranded DNA, insulin, and
LPS (1, 20). In agreement with our previous reports, we
found that only a small minority (9.4%) of antibodies
cloned from control new emigrant B cells was polyreactive
(Fig. 6; P   0.7 when our 31 clones are compared with
previously characterized new emigrant antibodies). When
combined with previously characterized new emigrant an-
tibodies, the proportion of polyreactive clones in the new
emigrant B cell compartment of healthy donors averaged
8.2% (Fig. 6; reference 1). In contrast, 50 and 37.8% of an-
tibodies expressed by XLA-ins and XLA-T117P B cells
Figure 4. Extensive Ig  secondary recombina-
tion in XLA B cells. J  (A) and V  (B) usage in
control new emigrant and XLA B cells. Control
new emigrant B cell sequences included sequences
shown in Table S1 and as reported previously (ref-
erence 1). Pie charts show proportion of different
J  genes with the number of sequences analyzed in-
dicated below. The V  locus (B) is shown clustered
into groups of V genes. *, statistically significant dif-
ference. P-values for differences between fractions
are stated in the text and were calculated by the
Fisher Exact Test.Ng et al. 931
were polyreactive (P   0.0001; Fig. 6). In addition, poly-
reactive antibodies from XLA B cells showed higher levels
of self-reactivity than polyreactive antibodies from control
new emigrant B cells (Fig. 6).
XLA polyreactive antibodies were enriched in long IgH
CDR3s, positively charged amino acids, aromatic residues
such as tyrosines encoded by the JH6 gene segment, and hy-
drophobic amino acids encoded by hydrophobic D2 and
D6 RF. These features have been associated with polyreac-
tivity (Fig. S1 and Tables S2 and S3, available at http://
www.jem.org/cgi/content/full/jem.20040920/DC1; refer-
ences 1, 20, and 31). XLA nonself-reactive antibodies signif-
icantly favored VH3 and JH4 gene usage and shorter IgH
CDR3s with hydrophilic D RF (Fig. S1 and Tables S2 and
S3). We conclude that almost half of the antibodies ex-
pressed by XLA B cells are highly polyreactive and that Btk
is essential for the removal of autoreactive B cells in humans.
Discussion
Human autoreactive B cells generated during early B cell
differentiation fail to be removed when BCR signaling is
altered in the absence of functional Btk. The majority of
XLA B cells express autoreactive and polyreactive antibod-
ies that display sequence features that favor DNA binding.
These include long IgH CDR3s enriched in aromatic and
positively charged amino acids (1, 20, 28, 31–33). In XLA
patients, long IgH CDR3s and positively charged amino
acids may result from increased nontemplate nucleotide ad-
dition at V-D and D-J junctions (34). XLA B cells re-
semble bone marrow early immature B cells from healthy
donors in that both B cell populations express similar per-
centages of autoreactive and polyreactive antibodies (1).
However, XLA B cells differ from early immature B cells
by expressing high levels of surface IgM, whereas early im-
mature B cells are surface IgM  (Fig. 1 and reference 1).
XLA B cells also display a unique antibody repertoire fa-
voring specific VHs and Ds using hydrophobic RF, whereas
early immature B cells from healthy donors do not, sug-
gesting that Btk-deficient B cells might be selected to ex-
press such autoreactive antibodies (1, 26). This apparent
positive selection for self-reactive BCRs in XLA B cells
might be explained by the fact that B cells are unable to
survive in the absence of BCR signaling (35, 36). In the
absence of Btk, BCR signaling is severely impaired in hu-
mans and the few XLA B cells that migrate to the periph-
ery may express autoreactive BCRs that are triggered by
self-antigens and may generate the intracellular signals re-
quired for their survival. Similarly to Btk-deficient mice,
XLA B cells that have undergone receptor editing may
have received additional signals that rescue maturation de-
fects, resulting from the absence of functional Btk (37).
The recent development of antileukemic drugs inhibiting
Btk signaling to promote the apoptosis of lymphoprolifera-
tive B cells would have to be studied carefully because
these drugs will interfere with normal BCR signaling and
affect B cell selection, and may allow the release of autore-
active B cells in treated patients (38).
Figure 5. A majority of XLA B cells express self-
reactive antibodies. (A) Data shown are from ELISAs
for anti–HEp-2 cell reactivity using recombinant anti-
bodies from 29 control new emigrant (left), 29 XLA-Ins
(middle), and 36 XLA-T117P B cells (right). Reactive
antibodies are indicated by clone number. Dotted lines
show ED38 positive control (reference 20). The per-
centage of autoreactive clones for each fraction is indi-
cated. P-values for differences between fractions are
shown and were calculated by the Fisher Exact Test.
The p-value increases up to 0.013 when control new
emigrant antibodies reported previously were included
(reference 1). (B) XLA B cells express ANAs. Antibod-
ies from XLA B cells show various patterns of ANA in-
cluding nucleolar (X2-20) and nuclear and cytoplasmic
patterns (X1-30, X2-53, X3-40, X3-69, and X-4-13).Btk-dependent Removal of Human Autoreactive B Cells 932
XLA B cells show a distinct IgL repertoire characterized
by increased upstream VL and downstream JL usage consis-
tent with extensive IgL secondary recombination (39). A
similar bias of the Ig  repertoire can be observed in anti-
body sequences obtained from EBV-transformed B cells
from other XLA patients (40). As a consequence of exten-
sive secondary recombination, we found an increased pro-
portion of   transcripts. However, XLA B cells have been
reported to favor Ig  expression (12). This apparent discrep-
ancy may result from different mutations of the BTK genes
that would allow residual Btk signaling and the down-regu-
lation of secondary recombination in some cases but not
others. The bias in the IgL repertoire that we observed in
XLA B cells may result from the negative selection of clones
that expressed innocuous BCRs and did not undergo IgL
secondary recombination, but failed to escape deletion in
the absence of Btk. Alternatively, newly arising XLA B cells
may not sense the expression of a BCR on their cell surface
and may remain equivalent to pre–B cells in that they
would keep recombining their IgL genes in the absence of
Btk-dependent signals initiated by the BCR. In contrast,
mouse Btk-deficient B cells do not show extensive IgL sec-
ondary recombination potentially because of Btk redun-
dancy with another tyrosine kinase from the same family,
Tec, in mouse but not in humans (41, 42). We previously
reported that IgL secondary recombination was prominent
in human Ig –deficient pro–B cells (26). IgL gene second-
ary recombination appears to be a default mechanism in the
absence of IgM signaling and this regulation suggests that
receptor editing at the pre–B/immature B cell stage may
require appropriate BCR signaling to be down-regulated
(26). Developing B cells that fail to generate such a signal
Figure 6. XLA B cells express polyreactive antibodies. Data shown are from ELISAs for reactivity with single-stranded DNA, double-stranded DNA,
insulin, and LPS. Percentages represent frequency of polyreactive antibodies. Dotted lines show ED38 positive control (reference 20). Reactive antibodies
are indicated by clone number. The frequency of polyreactive antibodies is significantly increased in XLA B cells (P   0.0001). *, control new emigrant
clones reported previously (reference 1).Ng et al. 933
may remain trapped in this editing compartment when in-
sufficient BCR density is expressed on the cell surface or
when expressing self-reactive BCRs (43–46).
The mechanisms that result in the development of au-
toimmunity in humans remain poorly understood. XLA as
well as common variable immunodeficiency patients whose
B cells show defects in BCR signaling may develop autoim-
mune diseases, suggesting that BCR signaling may play an
important role in counterselecting self-reactive B cells (11,
47). In this report, we provide the first evidence that the al-
teration of BCR signaling threshold in XLA patients results
in the release of self-reactive B cells in the periphery. Inter-
estingly, the alteration of TCR signaling threshold in SKG
(ZAP70W163C) mice allows the release of self-reactive T cells
in the periphery and the development of a rheumatoid ar-
thritis–like disease (48). Because TCR and BCR signaling
pathways share many molecules, it is likely that the alter-
ation of the signaling ability of one or more of those mole-
cules may result in the modification of TCR and BCR
thresholds and in the release of both self-reactive T and B
cells, thereby predisposing to autoimmunity.
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